The "LAG-3 Antagonist – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This "LAG-3 Antagonist – Pipeline Insight, 2021," report provides comprehensive ...
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
An international research team led by a University of Ottawa Faculty of Medicine investigator has revealed ultra-detailed ...
Kim and colleagues explain that previous work had led them to believe that blocking the effects of histamine in heart failure might be beneficial. From the 1104 consecutive subjects admitted to their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback